Exhibitors Search
AgingTarget Inc.
Booth no.
F60/H50
|
Exhibition
|
|KOREA LIFE SCIENCE |
|---|---|
|
Country
|
| Korea, South |
|
Address
|
| |
|
Tel
|
|+82--- |
|
Exhibits
|
| Development of novel anti-atherosclerotic drugs targeting vascular senescence, Development of multi-targeting anti-Alzheimer’s drugs |
|
Company Type
|
| Pharmaceutical / Drug Development Company , Biotech Venture / Startup |
Exhibitor Information
Founded in 2021, our company is a pharmaceutical and biotech startup currently developing anti-aging drugs and treatments for age-related diseases by targeting cellular senescence. Out of four pipeline candidates, we are focusing on the development of treatments for atherosclerosis and Alzheimer’s disease due to the need for strategic prioritization. Our company’s in-house new drug development center consists of a New Drug Synthesis Team capable of synthesizing novel structural compounds and a Pharmacological Evaluation Team capable of assessing the efficacy, pharmacology, and toxicity of the synthesized drugs. Our company has completed its Pre-A round of funding and is currently raising Series A funding. It holds three patents and has seven patent applications pending. Preclinical trials for atherosclerosis and Alzheimer’s disease drug candidates are scheduled for 2026?2027.
Exhibit Description
1. A novel atherosclerosis treatment based on targeting vascular senescence
: The atherosclerosis treatment currently under development by our company employs a novel approach based on targeting vascular senescence. By targeting blood vessels?which have a very long half-life?it can achieve fundamental therapeutic effects, reducing the frequency of dosing compared to existing treatments.
2. Multi-target, highly effective anti-Alzheimer's treatment
: The recently FDA-approved Alzheimer’s treatments all fall short of expectations because they target only amyloid beta. The Alzheimer’s treatment currently under development by our company is a multi-target, highly effective therapy that targets amyloid-beta, tau, and synaptic toxicity, offering the potential for enhanced therapeutic efficacy.
: The atherosclerosis treatment currently under development by our company employs a novel approach based on targeting vascular senescence. By targeting blood vessels?which have a very long half-life?it can achieve fundamental therapeutic effects, reducing the frequency of dosing compared to existing treatments.
2. Multi-target, highly effective anti-Alzheimer's treatment
: The recently FDA-approved Alzheimer’s treatments all fall short of expectations because they target only amyloid beta. The Alzheimer’s treatment currently under development by our company is a multi-target, highly effective therapy that targets amyloid-beta, tau, and synaptic toxicity, offering the potential for enhanced therapeutic efficacy.
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : A novel atherosclerosis treatment based on targeting vascular senescenceThe atherosclerosis treatment currently under development by our company employs a novel approach based on targeting vascular senescence. By targeting blood vessels?which have a very long half-life?it can achieve fundamental therapeutic effects, reducing the frequency of dosing compared to existing treatments.
-
Product Name : Multi-target, highly effective anti-Alzheimer's treatmentThe recently FDA-approved Alzheimer’s treatments all fall short of expectations because they target only amyloid beta. The Alzheimer’s treatment currently under development by our company is a multi-target, highly effective therapy that targets amyloid-beta, tau, and synaptic toxicity, offering the potential for enhanced therapeutic efficacy.
KYUNGYON EXHIBITION CORP.
